Erenumab for episodic migraine

References

• WHO . Headache disorders (2016). https://www.who.int/news-room/fact-sheets/detail/headache-disorders
   Google Scholar
• Steiner TJ , StovnerLJ , JensenRet al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J. Headache Pain21, 137 (2020).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society . The International Classification of Headache Disorders, 3rd edition. Cephalalgia38(1), 1–211 (2018).
   PubMed Web of Science ®Google Scholar
• Ashina M , HansenJM , DoTP , Melo-CarrilloA , BursteinR , MoskowitzMA. Migraine and the trigeminovascular system – 40 years and counting. Lancet Neurol.18(8), 795–804 (2019).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , HollandPR , Martins-OliveiraMet al. Pathophysiology of migraine: a disorder of sensory processing. Physiol. Rev.97, 553–622 (2017).
   PubMed Web of Science ®Google Scholar
• Pietrobon D , MoskowitzMA. Pathophysiology of migraine. Annu. Rev. Physiol.75, 365–391 (2013).
   PubMed Web of Science ®Google Scholar
• Dodick DW . A phase‐by‐phase review of migraine pathophysiology. Headache58, 4–16 (2018).
   PubMed Web of Science ®Google Scholar
• Burstein R , NosedaR , BorsookD. Migraine: multiple processes, complex pathophysiology. J. Neurosci.35(17), 6619–6629 (2015).
   PubMed Web of Science ®Google Scholar
• Edvinsson L , MulderH , GoadsbyPJ , UddmanR. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J. Auton. Nerv. Syst.70(1-2), 15–22 (1998).
   PubMedGoogle Scholar
• Tepper SJ . CGRP and headache: a brief review. Neurol. Sci.40(1), 99–105 (2019).
   PubMedGoogle Scholar
• Hansen JM , HaugeAW , OlesenJ , AshinaM. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia30(10), 1179–1186 (2010).
   PubMed Web of Science ®Google Scholar
• Curto M , CapiM , CipollaF , CisaleGY , MartellettiP , LionettoL. Ubrogepant for the treatment of migraine. Expert Opin. Pharmacother.21(7), 755–759 (2020).
   PubMed Web of Science ®Google Scholar
• Vu T , MaP , ChenJSet al. Pharmacokinetic–pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm. Res.34(9), 1784–1795 (2017).
   PubMed Web of Science ®Google Scholar
• de Hoon J , Van HeckenA , VandermeulenCet al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin. Pharmacol. Ther.103(5), 815–825 (2017).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Erenumab – product information: summary of product characteristics. www.ema.europa.eu/documents/product-information/aimovig-epar-product-information_en.pdf
   Google Scholar
• Zhou H , MascelliMA. Mechanisms of monoclonal antibody–drug interactions. Annu. Rev. Pharmacol. Toxicol.51, 359–372 (2011).
   PubMed Web of Science ®Google Scholar
• Xu Y , GabrielK , WangYet al. A multi-center, open-label, pharmacokinetic drug interaction study of erenumab and a combined oral contraceptive in healthy females. CNS Drugs33(5), 513–522 (2019).
   PubMed Web of Science ®Google Scholar
• de Hoon J , Van HeckenA , VandermeulenCet al. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. Cephalalgia39(1), 100–110 (2019).
   PubMed Web of Science ®Google Scholar
• Sun H , DodickDW , SilbersteinSet al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol.15(4), 382–390 (2016).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , ReuterU , HallströmYet al. A controlled trial of erenumab for episodic migraine. N. Engl. J. Med.377(22), 2123–2132 (2017).
   PubMed Web of Science ®Google Scholar
• Dodick DW , AshinaM , BrandesJLet al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia38(6), 1026–1037 (2018).
   PubMed Web of Science ®Google Scholar
• Reuter U , GoadsbyPJ , Lanteri-MinetMet al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet392(10161), 2280–2287 (2018).
   PubMed Web of Science ®Google Scholar
• Sakai F , TakeshimaT , TatsuokaYet al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache59(10), 1731–1742 (2019).
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M , GoadsbyPJ , ReuterUet al. Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study. J. Neurol. Neurosurg. Psychiatry92(5), 466–472 (2021).
   PubMed Web of Science ®Google Scholar
• Barbanti P , AuriliaC , EgeoGet al. Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study. Headache61(2), 363–372 (2021).
   PubMed Web of Science ®Google Scholar
• Broessner G , ReuterU , BonnerJHet al. The spectrum of response to erenumab in patients with episodic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. Headache60(9), 2026–2040 (2020).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , ReuterU , HallströmYet al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology95(5), e469–e479 (2020).
   PubMed Web of Science ®Google Scholar
• Chou DE , GoadsbyPJ , ReuterUet al. Sustained efficacy over 1 year of treatment with erenumab: results from the extension phase of the STRIVE study in episodic migraine. Neurology92(15), S38.005 (2019).
   Web of Science ®Google Scholar
• Schwedt T , ReuterU , TepperSet al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J. Headache Pain19(1), 1–8 (2018).
   PubMedGoogle Scholar
• Diener HC , AshinaM , RitterSet al. Erenumab prevents the occurrence of migraine attacks and not just migraine days: post-hoc analyses of a phase III study. Cephalalgia41(11–12), 1262–1267 (2021).
   PubMed Web of Science ®Google Scholar
• Pavlovic JM , PaemeleireK , GöbelHet al. Efficacy and safety of erenumab in women with a history of menstrual migraine. J. Headache Pain21(1), 1–9 (2020).
   PubMed Web of Science ®Google Scholar
• Buse DC , LiptonRB , HallströmYet al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia38(10), 1622–1631 (2018).
   PubMed Web of Science ®Google Scholar
• Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patient. https://clinicaltrials.gov/ct2/show/NCT03927144?term=erenumab&cond=Episodic+Migraine&draw=3&rank=1
   Google Scholar
• A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients (RESET BRAIN). https://clinicaltrials.gov/ct2/show/NCT03977649?term=erenumab&cond=Episodic+Migraine&draw=2&rank=5
   Google Scholar
• Smillie SJ , BrainSD. Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides45(2), 93–104 (2011).
   PubMed Web of Science ®Google Scholar
• Kudrow D , PascualJ , WinnerPKet al. Vascular safety of erenumab for migraine prevention. Neurology94(5), e497–e510 (2020).
   PubMed Web of Science ®Google Scholar
• Depre C , AntalikL , StarlingAet al. A randomized, double‐blind, placebo‐controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache58(5), 715–723 (2018).
   PubMed Web of Science ®Google Scholar
• Saely S , CroteauD , JawidzikL , BrinkerA , KortepeterC. Hypertension: a new safety risk for patients treated with erenumab. Headache61(1), 202–208 (2021).
   PubMed Web of Science ®Google Scholar
• Dodick DW , TepperSJ , AilaniJet al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache61(9), 1411–1420 (2021).
   PubMed Web of Science ®Google Scholar
• Kanaan S , HettieG , LoderE , BurchR. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia40(13), 1511–1522 (2020).
   PubMed Web of Science ®Google Scholar
• Ornello R , CasalenaA , FrattaleIet al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J. Headache Pain21(1), 32 (2020).
   PubMed Web of Science ®Google Scholar
• Robblee J , DevickKL , MendezN , PotterJ , SlonakerJ , StarlingAJ. Real‐world patient experience with erenumab for the preventive treatment of migraine. Headache60(9), 2014–2025 (2020).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ , ReuterU , Lanteri-MinetMet al. Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Neurology96(22), e2724–e2735 (2021).
   PubMed Web of Science ®Google Scholar
• Assessment of Prolonged Safety and Tolerability of in Migraine Patients in a Long-term Open-Label Study (APOLLON). https://clinicaltrials.gov/ct2/show/study/NCT04084314?term=erenumab&cond=Episodic+Migraine&draw=3&rank=12
   Google Scholar
• Ashina M , GoadsbyPJ , ReuterUet al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia39(11), 1455–1464 (2019).
   PubMed Web of Science ®Google Scholar
• Ashina M , GoadsbyPJ , ReuterUet al. Long‐term efficacy and safety of erenumab in migraine prevention: results from a 5‐year, open‐label treatment phase of a randomized clinical trial. Eur. J. Neurol.28(5), 1716–1725 (2021).
   PubMed Web of Science ®Google Scholar
• Zhu C , GuanJ , XiaoH , LuoW , TongR. Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Medicine98(52), (2019).
   Web of Science ®Google Scholar
• Zhu Y , LiuY , ZhaoJ , HanQ , LiuL , ShenX. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol. Sci.39(12), 2097–2106 (2018).
   PubMed Web of Science ®Google Scholar
• Lattanzi S , BrigoF , TrinkaEet al. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs79(4), 417–431 (2019).
   PubMed Web of Science ®Google Scholar
• De Matteis E , AffaitatiG , FrattaleIet al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol. Sci.42(8), 3297–3303 (2021).
   PubMed Web of Science ®Google Scholar
• Scheffler A , MesselO , WurthmannSet al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J. Headache Pain21(1), 84 (2020).
   PubMed Web of Science ®Google Scholar
• Kanaan S , HettieG , LoderE , BurchR. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia40(13), 1511–1522 (2020).
   PubMed Web of Science ®Google Scholar
• Sussman M , BennerJ , NeumannP , MenzinJ. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia38(10), 1644–1657 (2018).
   PubMed Web of Science ®Google Scholar
• Giannouchos TV , MitsikostasD-D , OhsfeldtRL , VozikisA , KoufopoulouP. Cost–effectiveness analysis of erenumab versus onabotulinumtoxin A for patients with chronic migraine attacks in Greece. Clin. Drug Investig.39(10), 979–990 (2019).
   PubMed Web of Science ®Google Scholar
• Mahon R , LangA , VoPet al. Cost–effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics39(3), 357–372 (2021).
   PubMed Web of Science ®Google Scholar
• Lipton RB , BrennanA , PalmerSet al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients. J. Med. Econ.21(7), 666–675 (2018).
   PubMed Web of Science ®Google Scholar